Vildapride M Tablets contain Vildagliptin 50 mg in combination with Metformin Hydrochloride 500 mg or 1000 mg. This dual oral antidiabetic combination provides complementary mechanisms of action to improve glycaemic control in adults with Type 2 Diabetes Mellitus.

Vildapride M Tablets combine a DPP-4 inhibitor with a biguanide to provide effective glycaemic control through complementary mechanisms. Vildagliptin enhances glucose-dependent insulin secretion by increasing endogenous incretin hormone activity, while Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity. This combination effectively controls both fasting and postprandial blood glucose levels while reducing the need for multiple medications.

Vildapride M Tablets are indicated for the treatment of Type 2 Diabetes Mellitus in adults when treatment with a single oral antidiabetic agent, together with diet and exercise, does not achieve adequate glycaemic control. It is used as an adjunct to lifestyle modification to improve long-term blood glucose management.

Vildapride M Tablets combine two antihyperglycaemic agents with complementary mechanisms of action. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases endogenous incretin hormone levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release. Metformin is a biguanide antihyperglycaemic agent that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral insulin sensitivity by increasing glucose uptake and utilization, resulting in improved overall glycaemic control.

The recommended dosage is one tablet taken orally twice daily with meals, or as directed by the treating physician. Dosage should be individualized based on the patient's glycaemic response and tolerability.

Vildapride M Tablets are contraindicated in patients with known hypersensitivity to Vildagliptin, Metformin, or any other component of the formulation.